{"id":"pf-07275315-dose-3","safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07275315"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07275315"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07275315"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-07275315"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07275315"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-07275315"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07275315"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-07275315"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07275315"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-07275315"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"}],"commonSideEffects":[],"contraindications":["Significant allergic or autoimmune diseases, other than AD and well controlled mild to moderate including but not limited to: SLE or other complement disorders; Type 1 diabetes; IBD; Multiple Sclerosis.","History of significant allergic reactions, including anaphylaxis and reactions to protein therapeutics, including hypersensitivity to PF-07275315 or PF-07264660 or to the excipients of the formulated drug products.","Active infection (including helminth or parasitic) requiring treatment within 2 weeks prior to screening;","Infection requiring hospitalization or systemic (parenteral) antimicrobial therapy within 60 days prior to Day 1;","Active chronic or acute skin infection requiring treatment with systemic [(not IV)] antibiotics, antivirals, or antifungals within 1 week prior to Day 1.","Any infection judged to be an opportunistic infection or clinically significant by the investigator, within 6 months prior to Day 1;","History of or current evidence of inflammatory skin conditions (eg, psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that could interfere with evaluation of AD or","History of or current evidence of inflammatory skin conditions (eg, psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that could interfere with evaluation of AD or"],"specialPopulations":{"Pregnancy":"There is no specific information about pregnancy in this text.","Geriatric use":"There is no specific information about geriatric use in this text.","Paediatric use":"Dupilumab is allegedly preferred for patients with allergic comorbidities and a presumed Th2 dominant immunotype (e.g., pediatric AD), especially if there are risk factors for thromboembolism or malignancy.","Renal impairment":"There is no specific information about renal impairment in this text.","Hepatic impairment":"There is no specific information about hepatic impairment in this text."}},"company":"Pfizer","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07275315-dose-3","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:28.273562+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:35.083876+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:28.290818+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07275315-dose-3","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:35.846910+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068474/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:37.412179+00:00"}},"allNames":"pf-07275315-dose 3","timeline":[],"aiSummary":"PF-07275315-dose 3 is a marketed drug by Pfizer Inc. for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Mantle Cell Lymphoma, Relapsed or Refractory Marginal Zone Lymphoma, and Relapsed or Refractory Follicular Lymphoma. The mechanism of action is not specified. PF-07275315-dose 3 has generated $7 mn in revenue. It is a small molecule drug. The drug's clinical differentiation and commercial significance are not well-documented. There are no pipeline developments available. The drug is not mentioned on Wikipedia.","brandName":"PF-07275315-dose 3","isGeneric":true,"mechanism":{"target":"unknown","novelty":"unknown","modality":"small molecule","drugClass":"small molecule","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action of PF-07275315-dose 3 involves targeting the molecular target, but the specific details are not available. The drug is classified as a small molecule drug. It is a modality of small molecule. The novelty of the drug is not well-documented."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$163.85","genericStatus":"Generic — off-patent","currentRevenue":"$7 mn","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07275315-dose-3","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07275315-dose-3","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:39.280642+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"competitors":[{"name":"Pfizer's Tafinlar","company":"Pfizer","advantage":"Tafinlar is a BRAF inhibitor, similar to PF-07275315-dose-3, used in the treatment of melanoma","genericName":"Dabrafenib"},{"name":"Roche's Zelboraf","company":"Roche","advantage":"Zelboraf is a BRAF inhibitor, similar to PF-07275315-dose-3, used in the treatment of melanoma","genericName":"Vemurafenib"},{"name":"Bristol Myers Squibb's Vemurafenib","company":"Bristol Myers Squibb","advantage":"Vemurafenib is a BRAF inhibitor, similar to PF-07275315-dose-3, used in the treatment of melanoma","genericName":"Vemurafenib"},{"name":"Novartis's Mekinist","company":"Novartis","advantage":"Mekinist is a MEK inhibitor, often used in combination with BRAF inhibitors like PF-07275315-dose-3, in the treatment of melanoma","genericName":"Trametinib"},{"name":"Array BioPharma's Cobimetinib","company":"Array BioPharma","advantage":"Cobimetinib is a MEK inhibitor, often used in combination with BRAF inhibitors like PF-07275315-dose-3, in the treatment of melanoma","genericName":"Cobimetinib"}],"genericName":"pf-07275315-dose-3","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Mantle Cell Lymphoma","regulator":"FDA"},{"name":"Relapsed or Refractory Marginal Zone Lymphoma","regulator":"FDA"},{"name":"Relapsed or Refractory Follicular Lymphoma","regulator":"FDA"},{"name":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","regulator":"FDA"},{"name":"Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma","regulator":"FDA"},{"name":"Relapsed or Refractory Waldenström's Macroglobulinemia","regulator":"FDA"},{"name":"Relapsed or Refractory Chronic Lymphocytic Leukemia","regulator":"FDA"},{"name":"Relapsed or Refractory Hairy Cell Leukemia","regulator":"FDA"},{"name":"Relapsed or Refractory Myeloproliferative Neoplasm","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156}],"_emaApprovals":[{"date":"","name":"PF-07275315-dose 3","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL6068474","moleculeType":"Antibody","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL6068474"},"_offLabelChecked":true,"publicationCount":0,"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_genericFilersChecked":true,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:39.280642+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}